Charlotte's Web Holdings, Inc.: Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment
"Progressing to Phase 2 of an IND study with the FDA marks an important milestone in the development of our proprietary hemp genetics as regulated medicine," said Bill Morachnick, Chief Executive ...
Charlotte's Web Announces Defloria To Enter Phase 2 FDA Clinical Trial For Autism Spectrum Disorder Treatment
Charlotte's Web Holdings, Inc. (" Charlotte's Web " or the " Company "), a market leader in hemp extract wellness products, is pleased to announce that the U.S. Food and Drug Administration (FDA) has ...
How the FDA's approval for food additives works, and why experts say a loophole allows companies to bypass it
Experts say that for decades, a legal loophole has allowed companies to include chemical additives that could be potentially ...
GSK plc (GSK): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Retailers’ Risk From DEI Policies Grows After Target And Starbucks Are Hit With Lawsuits
The legal battle against corporate DEI policies has escalated as Florida files suit against Target and Missouri against ...
F.D.A. Firings Decimated Teams Reviewing A.I. and Food Safety
Staff units evaluating high-tech surgical robots and insulin-delivery systems were gutted by Trump layoffs even though ...
USA Today3d
Target sued for defrauding shareholders about DEI
Target TGT.N has been sued for allegedly concealing the risks of its diversity and social initiatives, leading to a backlash that caused customers to flee and the stock price of the Minneapolis ...
Another Food Recall? Over 2 Million MadeGood Granola Bars Pulled
Over 2 million MadeGood granola bars were recalled due to metal contamination. Check the FDA recall list to see if your ...
Business Wire3d
Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results
Cerus Corporation (Nasdaq: CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024. Recent highlights inc ...
BioMarin's Narrow Moat Supported by Rare Disease Therapies and Developing Pipeline
BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million ...